CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma von Advani, Ranjana, Flinn, Ian, Popplewell, Leslie, Forero, Andres, Bartlett, Nancy L, Ghosh, Nilanjan, Kline, Justin, Roschewski, Mark, LaCasce, Ann, Collins, Graham P, Tran, Thu, Lynn, Judith, Chen, James Y, Volkmer, Jens-Peter, Agoram, Balaji, Huang, Jie, Majeti, Ravindra, Weissman, Irving L, Takimoto, Chris H, Chao, Mark P, Smith, Sonali M

Volltext

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies von Chao, Mark P., Takimoto, Chris H., Feng, Dong Dong, McKenna, Kelly, Gip, Phung, Liu, Jie, Volkmer, Jens-Peter, Weissman, Irving L., Majeti, Ravindra

Volltext

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells von Majeti, Ravindra, Chao, Mark P., Alizadeh, Ash A., Pang, Wendy W., Jaiswal, Siddhartha, Gibbs, Kenneth D., van Rooijen, Nico, Weissman, Irving L.

Volltext

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis von Jaiswal, Siddhartha, Jamieson, Catriona H.M., Pang, Wendy W., Park, Christopher Y., Chao, Mark P., Majeti, Ravindra, Traver, David, van Rooijen, Nico, Weissman, Irving L.

Volltext

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy von Chao, Mark P., Tang, Chad, Pachynski, Russell K., Chin, Robert, Majeti, Ravindra, Weissman, Irving L.

Volltext

Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia von CHAO, Mark P, ALIZADEH, Ash A, TANG, Chad, JAN, Max, WEISSMAN-TSUKAMOTO, Rachel, FEIFEI ZHAO, PARK, Christopher Y, WEISSMAN, Irving L, MAJETI, Ravindra

Volltext

Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker von Jan, Max, Chao, Mark P, Cha, Adriel C, Alizadeh, Ash A, Gentles, Andrew J, Weissman, Irving L, Majeti, Ravindra

Volltext

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies von Kohrt, Holbrook E., Houot, Roch, Goldstein, Matthew J., Weiskopf, Kipp, Alizadeh, Ash A., Brody, Josh, Müller, Antonia, Pachynski, Russell, Czerwinski, Debra, Coutre, Steven, Chao, Mark P., Chen, Lieping, Tedder, Thomas F., Levy, Ronald

Volltext

The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications von Chao, Mark P, Weissman, Irving L, Majeti, Ravindra

Volltext

The JAK2 V617F Mutation Occurs in Hematopoietic Stem Cells in Polycythemia Vera and Predisposes toward Erythroid Differentiation von Jamieson, Catriona H. M., Gotlib, Jason, Durocher, Jeffrey A., Chao, Mark P., Mariappan, M. Rajan, Lay, Marla, Jones, Carol, Zehnder, James L., Lilleberg, Stan L., Weissman, Irving L.

Volltext

Programmed cell removal: a new obstacle in the road to developing cancer von Chao, Mark P., Majeti, Ravindra, Weissman, Irving L.

Volltext

Myeloid Cell Origins, Differentiation, and Clinical Implications von Weiskopf, Kipp, Schnorr, Peter J, Pang, Wendy W, Chao, Mark P, Chhabra, Akanksha, Seita, Jun, Feng, Mingye, Weissman, Irving L

Volltext

Macrophages as mediators of tumor immunosurveillance von Jaiswal, Siddhartha, Chao, Mark P, Majeti, Ravindra, Weissman, Irving L

Volltext

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers von Sikic, Branimir I, Lakhani, Nehal, Patnaik, Amita, Shah, Sumit A, Chandana, Sreenivasa R, Rasco, Drew, Colevas, A Dimitrios, O'Rourke, Timothy, Narayanan, Sujata, Papadopoulos, Kyriakos, Fisher, George A, Villalobos, Victor, Prohaska, Susan S, Howard, Maureen, Beeram, Muralidhar, Chao, Mark P, Agoram, Balaji, Chen, James Y, Huang, Jie, Axt, Matthew, Liu, Jie, Volkmer, Jens-Peter, Majeti, Ravindra, Weissman, Irving L, Takimoto, Chris H, Supan, Dana, Wakelee, Heather A, Aoki, Rhonda, Pegram, Mark D, Padda, Sukhmani K

Volltext

Induced pluripotent stem cell modeling of malignant hematopoiesis von Chao, Mark P., Majeti, Ravindra

Volltext

Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease von Chao, Mark P., Gentles, Andrew J., Chatterjee, Susmita, Lan, Feng, Reinisch, Andreas, Corces, M. Ryan, Xavy, Seethu, Shen, Jinfeng, Haag, Daniel, Chanda, Soham, Sinha, Rahul, Morganti, Rachel M., Nishimura, Toshinobu, Ameen, Mohamed, Wu, Haodi, Wernig, Marius, Wu, Joseph C., Majeti, Ravindra

Volltext

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma von Chao, Mark P., Alizadeh, Ash A., Tang, Chad, Myklebust, June H., Varghese, Bindu, Gill, Saar, Jan, Max, Cha, Adriel C., Chan, Charles K., Tan, Brent T., Park, Christopher Y., Zhao, Feifei, Kohrt, Holbrook E., Malumbres, Raquel, Briones, Javier, Gascoyne, Randy D., Lossos, Izidore S., Levy, Ronald, Weissman, Irving L., Majeti, Ravindra

Volltext

Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies von Chao, Mark P

Volltext

Two faces of ET: CALR and JAK2 von Chao, Mark P., Gotlib, Jason

Volltext

slan+ Monocytes Kill Cancer Cells Coated in Therapeutic Antibody by Trogoptosis von Finotti, Giulia, Pietronigro, Enrica, Balanzin, Camillo, Lonardi, Silvia, Constantin, Gabriela, Chao, Mark P., Tecchio, Cristina, Vermi, William, Cassatella, Marco A.

Volltext